CDK2 Overexpression in Cancer and Potential Therapeutic Targeting
CDK2 Complex: A Central Regulator of the Cell Cycle
Cyclin-dependent kinase 2 (CDK2) plays a crucial role in controlling the progression of the cell cycle through its interactions with cyclins. The CDK2 complex is a protein kinase that regulates the transition from the G1 to S phase of the cell cycle, a critical step in cell growth and division.
Overexpression of CDK2 in Cancer
In many cancer cells, CDK2 is found to be significantly overexpressed. This overactivation is associated with uncontrolled cell growth and division, leading to tumor formation. The overexpression of CDK2 has been linked to various types of cancer, including breast, lung, and colorectal cancer.
Regulation of CDK2 Activity
The activities of CDK2 complexes are tightly regulated by a family of CDK inhibitors. These inhibitors prevent uncontrolled CDK2 activity and maintain proper cell cycle progression. Dysregulation of CDK inhibitors can lead to aberrant CDK2 activity and contribute to cancer development.
CDK2 as a Therapeutic Target
Due to its overexpression and role in cancer progression, CDK2 has emerged as an attractive target for cancer therapy. Several small-molecule inhibitors have been developed to specifically block CDK2 activity, preventing uncontrolled cell growth and division. These inhibitors hold promise in the development of novel cancer treatment strategies.
Komentar